AmerisourceBergen Co. (NYSE:ABC – Get Rating) CEO Steven H. Collis sold 11,480 shares of the company's stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $144.25, for a total transaction of $1,655,990.00. Following the completion of the transaction, the chief executive officer now directly owns 205,178 shares in the company, valued at approximately $29,596,926.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

AmerisourceBergen Stock Performance

NYSE ABC opened at $150.50 on Friday. The company has a 50-day simple moving average of $143.22 and a two-hundred day simple moving average of $147.72. The company has a quick ratio of 0.55, a current ratio of 0.92 and a debt-to-equity ratio of 8.96. AmerisourceBergen Co. has a 12-month low of $113.68 and a 12-month high of $167.19. The firm has a market cap of $31.52 billion, a price-to-earnings ratio of 17.26, a PEG ratio of 1.61 and a beta of 0.48.

AmerisourceBergen (NYSE:ABC – Get Rating) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $2.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.56 by $0.06. AmerisourceBergen had a net margin of 0.78% and a return on equity of 350.60%. The business had revenue of $60.06 billion during the quarter, compared to analyst estimates of $59.03 billion. During the same period in the prior year, the business posted $2.16 earnings per share. The company's revenue was up 12.5% on a year-over-year basis. On average, equities analysts forecast that AmerisourceBergen Co. will post 10.99 EPS for the current year.

AmerisourceBergen Announces Dividend

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Evercore ISI decreased their price target on shares of AmerisourceBergen to $165.00 in a report on Friday, June 3rd. StockNews.com raised shares of AmerisourceBergen from a "buy" rating to a "strong-buy" rating in a report on Tuesday. Mizuho upped their price target on shares of AmerisourceBergen from $139.00 to $162.00 in a report on Thursday, May 5th. Morgan Stanley decreased their price target on shares of AmerisourceBergen from $178.00 to $175.00 and set an "equal weight" rating on the stock in a report on Friday, May 27th. Finally, UBS Group increased their target price on AmerisourceBergen from $144.00 to $174.00 and gave the company a "buy" rating in a research note on Monday, June 13th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $173.45.

Institutional Trading of AmerisourceBergen

Institutional investors have recently modified their holdings of the company. Crewe Advisors LLC purchased a new stake in shares of AmerisourceBergen during the second quarter worth about $29,000. Herold Advisors Inc. purchased a new stake in shares of AmerisourceBergen during the first quarter worth about $31,000. Massmutual Trust Co. FSB ADV boosted its holdings in shares of AmerisourceBergen by 133.3% during the first quarter. Massmutual Trust Co. FSB ADV now owns 210 shares of the company's stock worth $32,000 after purchasing an additional 120 shares during the period. Cassady Schiller Wealth Management LLC purchased a new stake in shares of AmerisourceBergen during the fourth quarter worth about $33,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of AmerisourceBergen by 1,078.9% during the first quarter. EverSource Wealth Advisors LLC now owns 224 shares of the company's stock worth $35,000 after purchasing an additional 205 shares during the period. 64.17% of the stock is currently owned by hedge funds and other institutional investors.

AmerisourceBergen Company Profile

(Get Rating)

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.

Featured Stories

• Get a free copy of the StockNews.com research report on AmerisourceBergen (ABC)
• 2 Important Retail Stock Battles to Watch
• MarketBeat: Week in Review 8/8 – 8/12
• What Is WallStreetBets and What Stocks Are They Targeting?
• Institutions And Analysts Propel Jack In The Box Higher
• Can You Guess Which EV Stock Is Beating Tesla ?

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.